Kidswell Bio Corporation (4584.T)
JPY 126.0
(-0.79%)
JPY 126.0
(-0.79%)
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2023 | 343.58 Million JPY | -61.08% |
| 2022 | 882.83 Million JPY | 291.53% |
| 2021 | -460.93 Million JPY | -27.63% |
| 2020 | -361.15 Million JPY | 55.28% |
| 2019 | -807.57 Million JPY | 0.0% |
| Year | Net Debt | Net Debt Growth |
|---|---|---|
| 2024 Q1 | 1.23 Billion JPY | 259.52% |
| 2023 Q1 | 1.22 Billion JPY | 38.81% |
| 2023 Q4 | 343.58 Million JPY | 289.04% |
| 2023 Q3 | 88.31 Million JPY | -92.34% |
| 2023 Q2 | 1.15 Billion JPY | -5.93% |
| 2023 FY | 343.58 Million JPY | -61.08% |
| 2022 Q2 | 300.48 Million JPY | 0.0% |
| 2022 FY | 882.83 Million JPY | 291.53% |
| 2022 Q4 | 882.83 Million JPY | 53.43% |
| 2022 Q3 | 575.38 Million JPY | 91.49% |
| 2021 FY | -460.93 Million JPY | -27.63% |
| 2020 FY | -361.15 Million JPY | 55.28% |
| Name | Net Debt | Net Debt Difference |
|---|---|---|
| KOHJIN BIO CO LTD | 742.75 Million JPY | 53.742% |
| PRISM BioLab Co.,LTD | -1.13 Billion JPY | 130.3% |
| GNI Group Ltd. | -17.93 Billion JPY | 101.916% |
| Linical Co., Ltd. | -4.46 Billion JPY | 107.698% |
| Trans Genic Inc. | -221.16 Million JPY | 255.351% |
| MEDINET Co., Ltd. | -4.39 Billion JPY | 107.819% |
| Soiken Holdings Inc. | -4.79 Billion JPY | 107.173% |
| Cytori Cell Research Institute, Inc. | 1.43 Billion JPY | 76.032% |
| AnGes, Inc. | -3.79 Billion JPY | 109.047% |
| OncoTherapy Science, Inc. | -420.8 Million JPY | 181.65% |
| Nxera Pharma Co., Ltd. | 24.9 Billion JPY | 98.621% |
| Immuno-Biological Laboratories Co., Ltd. | -498.15 Million JPY | 168.972% |
| NanoCarrier Co., Ltd. | -466.34 Million JPY | 173.677% |
| Carna Biosciences, Inc. | -2.7 Billion JPY | 112.697% |
| CanBas Co., Ltd. | -1.88 Billion JPY | 118.197% |
| D. Western Therapeutics Institute, Inc. | -982.14 Million JPY | 134.984% |
| RaQualia Pharma Inc. | -3.39 Billion JPY | 110.114% |
| Chiome Bioscience Inc. | -1.03 Billion JPY | 133.211% |
| PeptiDream Inc. | 3.29 Billion JPY | 89.563% |
| Oncolys BioPharma Inc. | -972.59 Million JPY | 135.327% |
| Ribomic Inc. | -2.09 Billion JPY | 116.363% |
| SanBio Company Limited | -3.78 Billion JPY | 109.066% |
| Healios K.K. | -2.19 Billion JPY | 115.689% |
| BrightPath Biotherapeutics Co., Ltd. | -944.85 Million JPY | 136.364% |
| Kubota Pharmaceutical Holdings Co., Ltd. | -2.62 Billion JPY | 113.093% |
| Delta-Fly Pharma, Inc. | -1.41 Billion JPY | 124.247% |
| StemRIM | -8.41 Billion JPY | 104.085% |
| CellSource Co., Ltd. | -4.68 Billion JPY | 107.336% |
| FunPep Company Limited | -1.79 Billion JPY | 119.159% |
| Kringle Pharma, Inc. | -2.13 Billion JPY | 116.082% |
| Stella Pharma Corporation | -1.11 Billion JPY | 130.694% |
| TMS Co., Ltd. | -3.44 Billion JPY | 109.969% |
| Noile-Immune Biotech Inc. | -5.55 Billion JPY | 106.184% |
| Cuorips Inc. | -5.56 Billion JPY | 106.179% |
| K Pharma,Inc. | -3.26 Billion JPY | 110.519% |
| Takara Bio Inc. | -32.2 Billion JPY | 101.067% |
| ReproCELL Incorporated | -2.93 Billion JPY | 111.69% |
| PhoenixBio Co., Ltd. | -660.96 Million JPY | 151.983% |
| StemCell Institute Inc. | -2.83 Billion JPY | 112.112% |
| Japan Tissue Engineering Co., Ltd. | -2.06 Billion JPY | 116.628% |
| CellSeed Inc. | -2.01 Billion JPY | 117.077% |